Inactief instrument

Andere talen Aytu Bioscience Inc Nasdaq

Aandelen

US0547544033

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms	19/06
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024	30/05
Aytu BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	15/05
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q3 Revenue $18M, vs. Street Est of $17.4M	15/05
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M	14/02
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	24/01
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M	14/11
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party	26-10-23
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement	26-10-23
Aytu BioPharma, Inc. Announces Resignation of Christopher Brooke as Chief Operating Officer	06-10-23
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q4 Revenue $30.7M, vs. Street Est of $27.7M	27-09-23
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	27-09-23
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	27-09-23
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields	27-09-23
Aytu BioPharma to Present at LD Micro Main Event XVI Conference	14-09-23
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Israel and the Palestinian Authority	01-08-23
Aytu BioPharma, Inc. Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-OT(R) in Israel and the Arab Authority	31-07-23
Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement	10-07-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Aytu Bioscience Inc Nasdaq

Aandelen

US0547544033

Andere talen

Filters